Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.90
-0.38 (-3.70%)
Jun 2, 2026, 3:44 PM EDT - Market open
Atara Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 23.14 | 120.77 | 128.94 | 8.57 | 63.57 | 20.34 | |
Revenue Growth (YoY) | -29.35% | -6.33% | 1404.02% | -86.52% | 212.55% | - |
Cost of Revenue | 0.9 | 21.21 | 21.01 | 8.89 | - | - |
Gross Profit | 22.24 | 99.56 | 107.93 | -0.31 | 63.57 | 20.34 |
Selling, General & Admin | 18.38 | 26.25 | 39.89 | 50.91 | 71.55 | 78.8 |
Research & Development | 10.18 | 37.45 | 151.48 | 224.79 | 272.53 | 282 |
Total Operating Expenses | 28.55 | 63.7 | 191.37 | 275.69 | 344.09 | 360.8 |
Operating Income | -6.31 | 35.86 | -83.44 | -276.01 | -280.51 | -340.46 |
Interest Income | 0.5 | 0.68 | 2.11 | 5.43 | 3.06 | - |
Interest Expense | -3.61 | -3.79 | -4.62 | -5.29 | -0.37 | - |
Other Non-Operating Income (Expense) | -0.02 | -0.03 | 0.53 | -0.25 | 49.54 | - |
Total Non-Operating Income (Expense) | -3.13 | -3.14 | -1.98 | -0.11 | 52.22 | 0.73 |
Pretax Income | -9.44 | 32.72 | -85.42 | -276.11 | -228.29 | -340.1 |
Provision for Income Taxes | 0.03 | 0.03 | -0.01 | 0.02 | 0.01 | 0.05 |
Net Income | -9.47 | 32.69 | -85.4 | -276.13 | -228.3 | -340.14 |
Net Income to Common | -9.47 | 32.69 | -85.4 | -276.13 | -228.3 | -340.14 |
Shares Outstanding (Basic) | 13 | 13 | 7 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 14 | 13 | 7 | 4 | 4 | 4 |
Shares Change (YoY) | 54.40% | 69.84% | 76.77% | 3.83% | 8.88% | 26.63% |
EPS (Basic) | -0.76 | 2.61 | -11.41 | -65.19 | -56.00 | -90.75 |
EPS (Diluted) | -0.78 | 2.57 | -11.41 | -65.19 | -56.00 | -90.75 |
Shares Outstanding | 8.51 | 7.32 | 5.86 | 4.26 | 3.84 | 3.67 |
Free Cash Flow | -25.88 | -50.94 | -68.96 | -194.2 | -274.62 | -231.1 |
Free Cash Flow Per Share | -1.91 | -4.01 | -9.21 | -45.85 | -67.32 | -61.68 |
Gross Margin | 96.12% | 82.44% | 83.71% | -3.65% | 100.00% | 100.00% |
Operating Margin | -27.27% | 29.69% | -64.71% | -3219.48% | -441.25% | -1673.85% |
Profit Margin | -40.91% | 27.07% | -66.23% | -3220.88% | -359.12% | -1672.28% |
FCF Margin | -111.82% | -42.18% | -53.48% | -2265.25% | -431.98% | -1136.19% |
EBITDA | -5.96 | 37.98 | -78.39 | -271.18 | -274.86 | -331.12 |
EBITDA Margin | -25.75% | 31.45% | -60.79% | -3163.15% | -432.35% | -1627.91% |
EBIT | -6.31 | 35.86 | -83.44 | -276.01 | -280.51 | -340.46 |
EBIT Margin | -27.27% | 29.69% | -64.71% | -3219.48% | -441.25% | -1673.85% |
Effective Tax Rate | -0.33% | 0.09% | 0.01% | -0.01% | -0.01% | -0.01% |